Division Directors Conference
About the Event
Date:To Be Announced
Location:To Be Announced
Credit:No Credit
On Demand:Not Available
Registration Coming Soon
The Division Directors Conference is targeted to division directors. The primary content will focus on retention and recruitment issues regarding incorporation of diversity, equity, and inclusion and addressing financial challenges in division leadership.
Target Audience
Division directors
Learning Objectives
Upon completion of this activity, participants should be able to:
- List priorities and challenges facing the workplace in retention and recruitment
- Identify the vital issues involved with running academic divisions in rheumatology
See information from the 2023 meeting in the Division Directors Conference 2023 section below.
Program Schedule & Syllabi
Division Directors Conference 2024 Program Schedule
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Registration Fees
This conference is complimentary, but registration is required.
Corporate Support
The American College of Rheumatology thanks our corporate supporters and partners for their commitment to advancing rheumatology by supporting ACR and ARP programs and initiatives.
See current supporters, guidelines, and benefits of supporting the ACR.
This activity is not eligible for CME/MOC.
CME
Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
Designation Statement
The ACR designates this virtual activity for a maximum of 0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
View ACR's ACCME disclosure practices
See 2023 disclosures in the 2023 meeting section below.
The Division Directors Conference 2023 was one of the meetings held during the ACR Education Exchange.
CME & MOC Information
CME: 3:00
ABIM & ABP MOC: 3.00
CME credit must be claimed by March 26, 2024 at 11:59 PM ET.
MOC points must be claimed by December 31, 2023 at 11:59 PM ET.
See information about CME and MOC for all ACR Education Exchange meetings on the ACR Education Exchange page.
Target Audience
Division directors, program directors, and rheumatology division administrative staff.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the outcomes of the mentoring program focus group
- List priorities and challenges facing the workplace
- Identify the vital issues involved with running academic divisions in rheumatology
Program Schedule & Syllabi
View Division Directors Conference Schedule
ACR Education Exchange Program Schedule at a Glance
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Corporate Support
The American College of Rheumatology thanks our corporate supporters and partners for their commitment to advancing rheumatology by supporting ACR and ARP programs and initiatives.
See current supporters, guidelines, and benefits of supporting the ACR.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
The planning committee and faculty reported the following disclosures.
The following planning committee members have no relevant financial relationship(s) with ineligible companies to disclose.
- Charles Haberkern, MBA
- Rebecca Shepherd, MD, MBA
- Marcus Snow, MD
- Sarah Bayefsky, MD
- Adam Kilian, MD
- Bethany Marston, MD
- Benjamin Smith, PA-C
- Irene Tan, MD
- Melesia Tillman
- Saud Abaalkhail, MD
- Seth Berney, MD
- Anna Broder, MD, MSc
- Jim Oates, MD
- Debendra Pattanaik, MD
- Natasha Ruth, MD
- Sarah Baxter, MD, PhD
- Margaret Chang, MD, PhD
- Patrick Corrigan, DPT, PhD
- Ali Duarte, MD
- Ruth Fernandez Ruiz, MD, MSc
- Tate Johnson, MD
- Emily Smitherman, MD
- Louise Thoma, PhD, DPT
- Yu (Ray) Zuo, MD, MS
- Sean Fahey, MD
- Rebecca Manno, MD, MHS
- Ann Cameron Barr, MD
- Rashmi Dhital, MD
- Mohanad Elfishawi, MBBCh, MS
- Mario David Felix, MD
- Ibtissam Gad, MD
- Guy Katz, MD
- Karen Kruzer, MD
- Sara T. Patrizi, DO
- Jessica Perfetto, MD
- Didem Saygin, MD
- Austin Wheeler, MD
- Matthew Bunyard, MD
- Kevin Byrum, MD
- Sobia Hassan, RhMSUS, MRCP, MBBS
- Lisa Korn, PhD
- Aman Kugasia, MD
- Liana Fraenkel, MD, MPH
The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.
- Fotios Koumpouras, MD – AstraZeneca (Consultant/Speaker), GSK (Consultant/Speaker), Aurinia (Consultant), BMS (Consultant), Novartis (Consultant)
- Laura Sampson, PA-C – Novartis (Advisor Board), Eli Lilly (Advisory Board)
- Vaneet Sandhu, MD – GSK (Speaker), Aurinia (Speaker)
- Stacey Tarvin, MD – Pfizer (PI), UCB (PI), Roche (PI)
- Randy Cron, MD, PhD – Sobi (Consultant, CT Support), Pfizer (CT Adjudication Committee), Apollo Therapeutics (Consultant), AbbVie (CT Adjudication Committee), MedStudy (Board Review Lecturer), Lilly & Vindico Medical Education (Curbside Consultant/Speaker)
- Eyal Muscal, MD, MSc – Sobi (Consultant, Advisory Board)
- Shanthini Kasturi, MD, MS – GSK (Advisor)
- Hanna Kim, MD – Eli Lilly (Research Support)
- Maximilian Konig, MD – Argenx (Consultant), Revel (Consultant)
- Bella Mehta, MBBS, MS – Novartis (Educational Content Development)
- Naomi Patel, MD – FVC Health (Consultant), Alosa Health (Consultant)
- Kam Nola, MS, PharmD – Eli Lilly (Stock)
View ACR's ACCME disclosure practices
View ACR Education Exchange 2023 Disclosures
Corporate Support
The American College of Rheumatology thanks our corporate supporters and partners for their commitment to advancing rheumatology by supporting ACR and ARP programs and initiatives.
See current supporters, guidelines, and benefits of supporting the ACR.